Insurance firm Aviva has co-led a round for Owlstone Medical, whose roots can be traced back to University of Cambridge.

Lundbeck and Novo-backed nausea and vomiting therapy developer Acacia Pharma raised $49.6m in its initial global offering in Brussels.

Insurance firm Aviva has co-led a round for Owlstone Medical, developer of a breathalyser that will help detect lung and colorectal cancer.

Chorus, which had raised seed capital from Chernin Group and UTA Ventures, has elected to shut down its group fitness app shortly after its launch.

The neurodegenerative disease treatment spinout from University of Aberdeen has disclosed it raised $71m through a rights issue in October.

The immuno-oncology therapy developer, which is backed by Novo, Sanofi, EMS and Seattle Genetics, has raised $77m in venture funding.

The Genting-backed neurodegenerative disease treatment developer has disclosed it raised $71m through a rights issue in October.